Evaluation of Transcranial Photobiomodulation in Autism Spectrum Disorder

Autism Spectrum Disorder Clinical Trial

Official title:

Evaluation of Transcranial Photobiomodulation in Autism Spectrum Disorder: Double-Blind, Placebo-Controlled, Randomized Clinical Study of a Novel Approach

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05363982
• Other study ID #: 2021- P- 002646
• Status: Recruiting
• Phase: N/A
• Start date: February 11, 2022
• Est. completion date: February 11, 2025

Study information

• Verified date: March 2024
• Source: Massachusetts General Hospital
• Contact: Chloe Hutt Vater, BA
• Phone: 617-724-7301
• Email: chuttvater[@]mgh.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this 8-week double-blind randomized placebo-controlled study is to assess the tolerability, safety, and efficacy of tPBM in adult patients with ASD.

Description:

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by variable presentation of difficulties with socialization, reciprocal communication, and restrictive/repetitive behaviors. An increasingly higher prevalence of ASD is documented in each successive epidemiological survey and the disorder is now estimated to affect up to 2% of youth in the general population. This rise in prevalence is in part attributed to improved recognition of autism in intellectually capable populations.

Currently, there exists no approved treatments for core features of ASD. Instead, available treatment interventions target other psychiatric disorders that frequently co-occur with ASD, including attention, anxiety, and mood disorders.

Transcranial Photobiomodulation (tPBM) is a novel treatment approach based on application of an invisible, non-ionizing electromagnetic wave that results in metabolic modulation in tissues targeted. This intervention consists of exposing bilaterally the frontal brain to the electromagnetic wave that penetrates the skin and skull into brain tissue, is non-invasive and minimally dissipated as thermal energy. The benefits of tPBM are wavelength specific. Electromagnetic wave at 850nm is absorbed by cytochrome c oxidase, a specific chromophore in mitochondria and is associated with increased adenosine triphosphate (ATP) production through the respiratory chain. Ultimately, the increased ATP production leads to increased energy metabolism and activity for the cell, and it is hypothesized that a signaling cascade is also activated promoting cellular plasticity and cytoprotection.

These properties of the tPBM have led to novel therapeutic applications in neurology. In acute ischemic stroke subjects, acute treatment with the tPBM led to significantly better outcome as compared to sham. These results were confirmed in a different cohort of stroke patients with mild to moderate severity of illness. Both studies on stroke subjects showed no significant difference in rate of adverse events, as well as serious adverse events, between the tPBM and sham treated subjects. The tPBM has also been used as a treatment of alopecia and in animal models for methanol-induced retinal toxicity. The tPBM is already widely used for non-invasive assessment of brain function, replacing functional magnetic resonance imaging (fMRI), in studies of infants and young adults, under the name of Near Infrared Spectroscopy) underscoring the relatively low risk of tPBM. The major risk of tPBM when using a laser as the light source is associated with accidental retinal exposure, when beams are projected through the lens, with increased risk of macular degeneration. Light emitting diode (LED) light does not share the same risk level as laser light sources and this clinical trial will have multiple protections to safeguard against this risk.

Proposed treatment with tPBM has been previously studied in patients with Major Depressive Disorder (MDD). MDD has been associated with deficits in brain bioenergetic metabolism. In an experimental model of depression, the mitochondrial respiratory chain was found to be inhibited by chronic stress. Depressed subjects have also significantly lower production of ATP (an energy vector) in their muscle tissue and greater incidence of deletions in their mitochondrial DNA. Data from magnetic resonance spectroscopy in subjects with MDD showed that response to the augmentation of a selective serotonin reuptake inhibitor (SSRI) with triiodothyronine (a thyroid hormone) is associated with restoration of the levels of ATP in the brain. A preliminary open study in 10 depressed subjects has shown that the tPBM was safe, effective and well tolerated. More recently, efficacy and safety of tPBM was also explored in treatment of ASD with promising results and no serious adverse events. In that study, 40 participants received eight 5-min laser light applications to the base of the skull and temporal areas across 4-week period (2 applications per week). A pulsed laser of 635nm was compared to placebo (very weak LEDs) and was shown to be associated with significant improvement in ASD symptoms. Tissue penetration varies at different wavelengths, with 800-850nm range penetrating into deep tissue compared to that of 635nm.

More recently, the investigators completed a prospective, 8-week open-label treatment trial of tPBM in 10 adult patients with moderate to severe level of ASD. Short-term tPBM was well tolerated and was effective in reducing symptom severity of ASD and comorbid ADHD. In addition, tPBM treatment was associated with improvements in executive functions, specifically in functional domains of cognitive flexibility and emotional control, planning and organization, response inhibition and significant improvement in overall function. Treatment with tPBM was well tolerated, and there were no serious adverse events. One subject experienced headache 8 hours after first treatment, and another patient had insomnia after the first treatment episode. Both patients recovered spontaneously and required no changes to study treatments. Current project involves a double-blind randomized clinical trial of tPBM in adult patients with ASD.

The main aim of this 8-week, prospective, placebo (sham) controlled study is to evaluate the efficacy, safety, and tolerability of tPBM with near-infrared light in intellectually capable adults with ASD. Because the tPBM is a non-ionizing radiation, multiple sessions are expected to be safe.

The tPBM treatment can be completed in the comfort of participants' homes, while monitoring their safety and response during scheduled visits. This clinical trial will answer whether tPBM has an effect on ASD symptoms and whether it is safe and acceptable among patients with ASD, for whom frequent visits otherwise would be prohibitive or render it inaccessible.

The advantage of the tPBM treatment approach as compared to pharmacotherapy is that adherence can be easily monitored with device recordings, and the patient is not required to ingest any substance. This proposed study will contribute to answer the question of whether tPBM has an effect on ASD symptoms and whether it is acceptable in minority populations, thus justifying further studies and investments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: February 11, 2025
• Est. primary completion date: February 11, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 59 Years

Eligibility

Inclusion Criteria:

• Male or female participants between 18 and 59 years of age (inclusive)

• Fulfills Diagnostic and Statistical Manual-5th edition diagnostic criteria for autism spectrum disorder as established by the clinical diagnostic interview.

• Participants with at least moderately severity of ASD symptoms as demonstrated by SRS raw score = 85 and CGI-ASD severity score = 4

• Participants must understand the nature of the study. Participants must be deemed not to have impaired decision-making capacity and must have the capacity to provide direct informed consent. Participants must sign an Institutional Review Board-approved informed consent form before initiation of any study procedures.

• Participants must have a level of understanding sufficient to communicate with the investigator and study coordinator, and to cooperate with all tests and examinations required by the protocol.

• Participant experiencing a major psychiatric disorder will be allowed to participate in the study provided they do not meet any exclusionary criteria.

• Women of child-bearing potential must use a double-barrier method for birth control (e.g. condoms with spermicide) if sexually active.

• The subject is willing to participate in this study.

Exclusion Criteria:

• Impaired intellectual capacity (clinically determined). Participants' intellectual capacity will be assessed during the clinical evaluation and determination will be based on intact communicative language, ability to take personal care, history of holding a job and completion of high school (or equivalency credential), and no history of intellectual disability.

• Participant is unable to communicate due to delay in, or total lack of, spoken language development (grossly impaired language skills)

• Clinically unstable psychiatric conditions or judged to be at serious safety risk to self (suicidal risk) or others (within past 30 days).

• Subjects currently (within past 30 days) experiencing significant symptoms of major psychiatric disorders as clinically determined.

• Subjects with an unstable medical condition (that requires clinical attention).

• Active suicidal or homicidal ideation, as determined by clinical screening.

• The subject has a significant skin condition at the procedure sites (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo).

• The subject has an implant of any kind in the head (e.g. stent, clipped aneurysm, embolised arteriovenous malformation, implantable shunt - Hakim valve).

• Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment (verteporfin - for age related macular degeneration; Aminolevulinic Acid- for actinic keratoses; Photofrin (porfimer sodium) - for esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA)- for non-melanoma skin cancer)

• Current treatment with a psychotropic medication on a dose that has not been stable for at least 4 weeks prior to initiating study treatment.

• Investigator and his/her immediate family, defined as the investigator's spouse, parent, child, grandparent, or grandchild.

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autistic Disorder
• Child Development Disorders, Pervasive

Intervention

Device:
• Transcranial Photobiomodulation (tPBM)
Transcranial Photobiomodulation (tPBM) is a novel treatment approach based on application of an invisible, non-ionizing electromagnetic wave that results in metabolic modulation in tissues targeted. This intervention consists of exposing bilaterally the frontal brain to the electromagnetic wave that penetrates the skin and skull into brain tissue, is non-invasive and minimally dissipated as thermal energy. Other Names: Niraxx G1 Headband
• Placebo/ Sham
The sham treatment will consist of applying all the procedures for the delivery of tPBM, but will not deliver light.

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

References & Publications (33)

Achenbach, T. M. and L. A. Rescorla (2003). Manual for ASEBA Adult Forms & Profiles. Burlington, VT, University of Vermont, Research Center for Children, Youth, & Families.

Adler LA, Spencer T, Faraone SV, Kessler RC, Howes MJ, Biederman J, Secnik K. Validity of pilot Adult ADHD Self- Report Scale (ASRS) to Rate Adult ADHD symptoms. Ann Clin Psychiatry. 2006 Jul-Sep;18(3):145-8. doi: 10.1080/10401230600801077. — View Citation

American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA, American Psychiatric Publishing.

Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain Behav Immun. 2011 Jan;25(1):40-5. doi: 10.1016/j.bbi.2010.08.003. Epub 2010 Aug 10. — View Citation

Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators and Centers for Disease Control and Prevention (2012).

Blumberg SJ, Bramlett MD, Kogan MD, Schieve LA, Jones JR, Lu MC. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012. Natl Health Stat Report. 2013 Mar 20;(65):1-11, 1 p following 11. — View Citation

Cassano P, Cusin C, Mischoulon D, Hamblin MR, De Taboada L, Pisoni A, Chang T, Yeung A, Ionescu DF, Petrie SR, Nierenberg AA, Fava M, Iosifescu DV. Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. Psychiatry J. 2015;2015:352979. doi: 10.1155/2015/352979. Epub 2015 Aug 19. — View Citation

Cassano P, Petrie SR, Hamblin MR, Henderson TA, Iosifescu DV. Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. Neurophotonics. 2016 Jul;3(3):031404. doi: 10.1117/1.NPh.3.3.031404. Epub 2016 Mar 4. — View Citation

Constantino, J. N. and C. P. Gruber (2012). The Social Responsiveness Scale Manual, Second Edition (SRS-2). Los Angeles, CA, Western Psychological Services.

Eells JT, Henry MM, Summerfelt P, Wong-Riley MT, Buchmann EV, Kane M, Whelan NT, Whelan HT. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3439-44. doi: 10.1073/pnas.0534746100. Epub 2003 Mar 7. — View Citation

Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-6. — View Citation

Endicott, J., R. L. Spitzer, J. L. Fleiss and J. Cohen (1976).

Gardner A, Johansson A, Wibom R, Nennesmo I, von Dobeln U, Hagenfeldt L, Hallstrom T. Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord. 2003 Sep;76(1-3):55-68. doi: 10.1016/s0165-0327(02)00067-8. — View Citation

Hamilton, M. (1959).

Hamilton, M. (1960).

Hollingshead, A. B. (1975). Four Factor Index of Social Status. New Haven, CT, Yale Press.

Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, Fava M, Renshaw PF. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry. 2008 Jun 15;63(12):1127-34. doi: 10.1016/j.biopsych.2007.11.020. Epub 2008 Jan 22. — View Citation

Joshi G, Petty C, Wozniak J, Henin A, Fried R, Galdo M, Kotarski M, Walls S, Biederman J. The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: a large comparative study of a psychiatrically referred population. J Autism Dev Disord. 2010 Nov;40(11):1361-70. doi: 10.1007/s10803-010-0996-9. — View Citation

Kim EA, Kim BG, Yi CH, Kim IG, Chae CH, Kang SK. Macular degeneration in an arc welder. Ind Health. 2007 Apr;45(2):371-3. doi: 10.2486/indhealth.45.371. — View Citation

Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, Borenstein P, Andersson B, Perez J, Caparo C, Ilic S, Oron U. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke. 2007 Jun;38(6):1843-9. doi: 10.1161/STROKEAHA.106.478230. Epub 2007 Apr 26. — View Citation

Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009;29(5):283-92. doi: 10.2165/00044011-200929050-00001. — View Citation

Leisman G, Machado C, Machado Y, Chinchilla-Acosta M. Effects of Low-Level Laser Therapy in Autism Spectrum Disorder. Adv Exp Med Biol. 2018;1116:111-130. doi: 10.1007/5584_2018_234. — View Citation

Mochizuki-Oda N, Kataoka Y, Cui Y, Yamada H, Heya M, Awazu K. Effects of near-infra-red laser irradiation on adenosine triphosphate and adenosine diphosphate contents of rat brain tissue. Neurosci Lett. 2002 May 3;323(3):207-10. doi: 10.1016/s0304-3940(02)00159-3. — View Citation

National Institute of Mental Health (1985).

Rezin GT, Cardoso MR, Goncalves CL, Scaini G, Fraga DB, Riegel RE, Comim CM, Quevedo J, Streck EL. Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem Int. 2008 Dec;53(6-8):395-400. doi: 10.1016/j.neuint.2008.09.012. Epub 2008 Sep 27. — View Citation

Roth, R. M., P. K. Isquith and G. A. Gioia (2004). Brief-Atm Self report form, Psychological Assessment Resources, Inc.

Schiffer F, Johnston AL, Ravichandran C, Polcari A, Teicher MH, Webb RH, Hamblin MR. Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety. Behav Brain Funct. 2009 Dec 8;5:46. doi: 10.1186/1744-9081-5-46. — View Citation

Siniscalco D, Schultz S, Brigida AL, Antonucci N. Inflammation and Neuro-Immune Dysregulations in Autism Spectrum Disorders. Pharmaceuticals (Basel). 2018 Jun 4;11(2):56. doi: 10.3390/ph11020056. — View Citation

Spencer TJ, Adler LA, Meihua Qiao, Saylor KE, Brown TE, Holdnack JA, Schuh KJ, Trzepacz PT, Kelsey DK. Validation of the adult ADHD investigator symptom rating scale (AISRS). J Atten Disord. 2010 Jul;14(1):57-68. doi: 10.1177/1087054709347435. Epub 2009 Sep 30. — View Citation

StataCorp (2019). Stata Statistical Software: Release 16. College Station, TX.

Yamaura M, Yao M, Yaroslavsky I, Cohen R, Smotrich M, Kochevar IE. Low level light effects on inflammatory cytokine production by rheumatoid arthritis synoviocytes. Lasers Surg Med. 2009 Apr;41(4):282-90. doi: 10.1002/lsm.20766. — View Citation

Zhang Q, Ma H, Nioka S, Chance B. Study of near infrared technology for intracranial hematoma detection. J Biomed Opt. 2000 Apr;5(2):206-13. doi: 10.1117/1.429988. — View Citation

Zivin, J. A., G. W. Albers, N. Bornstein, T. Chippendale, B. Dahlof, T. Devlin, M. Fisher, W. Hacke, W. Holt, S. Ilic, S. Kasner, R. Lew, M. Nash, J. Perez, M. Rymer, P. Schellinger, D. Schneider, S. Schwab, R. Veltkamp, M. Walker, J. Streeter, E. NeuroThera and I. Safety Trial (2009).

* Note: There are 33 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ASD symptoms as measured by change through study completion, on the Clinical Global Impression of Improvement of Autism Spectrum Disorder (CGI-ASD-I)	Primary outcome measure of efficacy will be change in ASD symptoms as measured by change through study completion, an average of 8 weeks, on the clinician-rated CGI-ASD-I. Responders will be defined as those who demonstrate a =25% change in Social Responsiveness Scale-2nd Edition total score and a score of 2 or 1 on the CGI-ASD-Improvement subscale ("much" or "very much improved").	through study completion, an average of 8 weeks
Primary	ASD symptoms as measured by change through study completion on the Social Responsiveness Scale-2nd Edition (SRS-2)	Primary outcome measure of efficacy will be change in ASD symptoms as measured by change through study completion, an average of 8 weeks, on the SRS-2. Responders will be defined as those who demonstrate a =25% change in SRS-2 total score and a score of 2 or 1 on the CGI-ASD-Improvement subscale ("much" or "very much improved").	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in social cognition functions	Treatment-related changes in associated social cognition will be assessed by change in total score on Massachusetts General Hospital Social Emotional Competence Scale (MGH-SEC Scale) on which higher scores mean more severe clinical presentation	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in associated executive functions	Treatment-related changes in associate executive functions will be assessed by Behavior Rating Inventory of Executive Function-Adult Self Report Version (BRIEF-A) on which higher scores mean more severe clinical presentation	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in associated psychopathology (Attention Deficit Hyperactivity Disorder, ADHD)	Treatment-related changes in associated ADHD will be assessed by Adult ADHD Self-Report Scale (ASRS) on which higher scores mean more severe clinical presentation	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in associated psychopathology (Attention Deficit Hyperactivity Disorder, ADHD)	Treatment-related changes in associated ADHD will be assessed by Adult ADHD Investigator Symptom Report Scale (AISRS) on which higher scores mean more severe clinical presentation	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in associated psychopathology (Attention Deficit Hyperactivity Disorder, ADHD)	Treatment-related changes in associated ADHD will be assessed by Clinical Global Impression of Improvement in ADHD scale (CGI-ADHD-I) on which lower score means improvement	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in associated psychopathology (depression)	Treatment-related changes in associated depression will be assessed by Hamilton Depression Scale on which higher scores mean more severe clinical presentation	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in associated psychopathology (depression)	Treatment-related changes in associated depression will be assessed by Clinical Global Impression of Improvement in Depression scale (CGI-Depression-I) on which lower score means improvement	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in associated psychopathology (anxiety)	Treatment-related changes in associated depression will be assessed by Hamilton Anxiety Scale on which higher scores mean more severe clinical presentation	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in associated psychopathology (anxiety)	Treatment-related changes in associated depression will be assessed by Clinical Global Impression of Improvement in Anxiety scale (CGI-Anxiety-I) on which lower score means improvement	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in associated psychopathology	Treatment-related changes in associated psychopathology will be measured by Adult Behavior Checklist (ABCL) on which higher scores mean more severe clinical presentation	through study completion, an average of 8 weeks
Secondary	Treatment-related changes in quality of life	Treatment-related changes in quality of life will be measured by Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) on which higher scores mean greater satisfaction and enjoyment	through study completion, an average of 8 weeks
Secondary	The monitoring of treatment-emergent adverse events	Safety and tolerability will be assessed by Treatment-emergent Adverse Events Log (CTAE)	through study completion, an average of 8 weeks
Secondary	The monitoring of treatment-emergent adverse events	Safety and tolerability will be assessed by tPBM Self-Report Questionnaire (TSRQ) on which higher scores mean more severe discomfort	through study completion, an average of 8 weeks